JPH01228483A - Antitumor agent - Google Patents
Antitumor agentInfo
- Publication number
- JPH01228483A JPH01228483A JP63054319A JP5431988A JPH01228483A JP H01228483 A JPH01228483 A JP H01228483A JP 63054319 A JP63054319 A JP 63054319A JP 5431988 A JP5431988 A JP 5431988A JP H01228483 A JPH01228483 A JP H01228483A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- strain
- antitumor agent
- medium
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims abstract description 8
- 241000187759 Streptomyces albus Species 0.000 claims abstract description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims abstract description 5
- 238000000921 elemental analysis Methods 0.000 claims abstract description 4
- 238000002844 melting Methods 0.000 claims abstract description 4
- 230000008018 melting Effects 0.000 claims abstract description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000000862 absorption spectrum Methods 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 21
- 206010006187 Breast cancer Diseases 0.000 abstract description 7
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 7
- 210000002950 fibroblast Anatomy 0.000 abstract description 4
- 230000007935 neutral effect Effects 0.000 abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 238000013019 agitation Methods 0.000 abstract description 2
- 238000012258 culturing Methods 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 238000005273 aeration Methods 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 27
- 230000018109 developmental process Effects 0.000 description 10
- 239000000975 dye Substances 0.000 description 10
- 229920001817 Agar Polymers 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000028070 sporulation Effects 0.000 description 5
- 241000258957 Asteroidea Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013535 sea water Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- -1 texturin Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000625 blastula Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000012534 cell culture medium component Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- BBBFYZOJHSYQMW-LGDQNDJISA-N (2s)-2,4-diamino-4-oxobutanoic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC(=O)[C@@H](N)CC(N)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O BBBFYZOJHSYQMW-LGDQNDJISA-N 0.000 description 1
- UQZSVIGPZAULMV-DKWTVANSSA-N (2s)-2,4-diamino-4-oxobutanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)[C@@H](N)CC(N)=O UQZSVIGPZAULMV-DKWTVANSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- XJMWHXZUIGHOBA-UHFFFAOYSA-N azane;propanoic acid Chemical compound N.CCC(O)=O XJMWHXZUIGHOBA-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000007613 bennett's agar Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001362 calcium malate Substances 0.000 description 1
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 description 1
- 229940016114 calcium malate Drugs 0.000 description 1
- 235000011038 calcium malates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000019631 mycelium development Effects 0.000 description 1
- 150000002815 nickel Chemical class 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000006877 oatmeal agar Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Description
【発明の詳細な説明】 (産業上の利用分野) 本発明は、抗腫瘍剤に関するものである。[Detailed description of the invention] (Industrial application field) TECHNICAL FIELD The present invention relates to antitumor agents.
(従来の技術及び発明が解決しようとする問題点)
従来、抗腫瘍作用を有する物質として種々の化合物が提
案されているが、腫瘍の多様性の問題点から、更に種々
の抗腫瘍作用を有する化合物が求められている。本発明
者らは、ストレプトマイセス属に属する菌に着目して、
抗腫瘍作用を有する化合物を得るべく種々検討した結果
、ストレプトマイセスアルバス(Streptomyc
esalbus ) A 2 g 2株が産生ずる下記
の理化学的性質を有する化合物が、抗腫瘍作用を有する
ことを見いだした。(Prior Art and Problems to be Solved by the Invention) Conventionally, various compounds have been proposed as substances having antitumor effects, but due to the problem of tumor diversity, there are still many compounds with various antitumor effects. A compound is needed. The present inventors focused on bacteria belonging to the genus Streptomyces,
As a result of various studies to obtain compounds with antitumor effects, Streptomyces albus (Streptomyces albus)
It has been found that a compound produced by the A.sub.esalbus A.sub.2 g2 strain and having the following physicochemical properties has an antitumor effect.
(a) 分子量:、267
(b) 分子式: CIl H13N3O5(C)
元素分析値
(CIIH13N3OS ・CH3OHとして)(d)
融 点: 10/、!i 〜IOA、O℃(e) 溶
解性:水、メタノール、エタノール、ジオキサン及びピ
リジンに可溶で、
クロロホルム及び酢酸エチルに難
溶である。(a) Molecular weight:, 267 (b) Molecular formula: CIl H13N3O5(C)
Elemental analysis value (as CIIH13N3OS ・CH3OH) (d)
Melting point: 10/,! i ~ IOA, O°C (e) Solubility: Soluble in water, methanol, ethanol, dioxane and pyridine, slightly soluble in chloroform and ethyl acetate.
(f) 第1図に示す紫外部吸収スペクトルを有する
。(f) It has the ultraviolet absorption spectrum shown in FIG.
(g) 第二図に示す核磁気共鳴スペクトルを有する
。(g) It has the nuclear magnetic resonance spectrum shown in Figure 2.
(h) 第3図に示す赤外線吸収スペクトルを有する
。(h) It has an infrared absorption spectrum shown in FIG.
従来、本発明化合物と類似の理化学的性質を有する抗生
物質が抗菌活性を有することが知られているが、該抗生
物質が抗腫瘍作用を有することについては全く記載され
ていない(特公昭ダj−20!!9号公報)。Conventionally, it has been known that antibiotics with similar physicochemical properties to the compounds of the present invention have antibacterial activity, but there has been no description that these antibiotics have antitumor effects (Tokuko Shoda J. -20!!9 Publication).
本発明者らは、今般初めて上記化合物が後述の実施例に
示したように、ヒト繊維芽細胞やマウス乳癌細胞の増殖
を抑制することを見い出し、本発明を完成するに至った
。The present inventors have recently discovered for the first time that the above compound suppresses the proliferation of human fibroblasts and mouse breast cancer cells, as shown in the Examples below, and have completed the present invention.
(問題点を解決するための手段)
即ち本発明の要旨は、前記の理化学的性質を有する化合
物を有効成分とする抗腫瘍剤に存する。(Means for Solving the Problems) That is, the gist of the present invention resides in an antitumor agent containing a compound having the above-mentioned physicochemical properties as an active ingredient.
以下、本発明を説明するに、本発明の上記化合物は後述
のようにストレプトマイセス・アルバスAλg2株を培
養することによって得ることができる。かかるストレプ
トマイセスアルバスA232株の菌学的性状は下記の通
りである。Hereinafter, to explain the present invention, the above-mentioned compound of the present invention can be obtained by culturing Streptomyces albus Aλg2 strain as described below. The mycological properties of the Streptomyces albus A232 strain are as follows.
/ 形態学的特徴
合成培地上で、コロニーは白色〜黄味臼を呈する。基底
菌糸はよ(発達し、分枝する。/ Morphological Characteristics Colonies appear white to yellowish in color on synthetic media. The basal hyphae are well developed and branched.
気菌糸の発達は貧弱で気菌糸上に分節型の長い胞子連鎖
部を形成する。胞子連鎖部はゆるやかなラセン状に巻か
れている。胞子表面は平滑。胞子は短円筒形で、その大
きさはo、A〜o、 g x 0、ワ〜/、/μmであ
る。Aerial hyphae are poorly developed and long segmented spore chains are formed on the aerial hyphae. The spore chain is wound in a loose spiral. Spore surface is smooth. The spores are short cylindrical, and their sizes are o, A~o, g x 0, Wa~/, /μm.
コ 各種培地上における生育状態(27℃、/ダル2フ
日間培養後の特徴)
イースト・麦芽寒天培地(Isp、a2)生育良好、白
色。気菌糸の発達旺盛。胞子の形成は貧弱。コロニー裏
面は黄茶色〜黄味白。可溶性色素なし。Growth status on various media (characteristics after 2 days of culture at 27°C): Good growth on yeast/malt agar medium (Isp, A2), white color. Strong development of aerial mycelium. Spore formation is poor. The underside of the colony is yellowish brown to yellowish white. No soluble dyes.
オート・ミール寒天培地(ISP /i6J )生育貧
弱、白色。気菌糸の発達貧弱。胞子の着生貧弱。コロニ
ー裏面は白色。可溶性色素なし。Oat meal agar medium (ISP/i6J) Poor growth, white color. Poor development of aerial hyphae. Poor spore settlement. The underside of the colony is white. No soluble dyes.
スターチ・無機塩寒天培地(ISPAj)生育貧弱、黄
味白色。気菌糸の発達貧弱。Poor growth on starch/inorganic salt agar medium (ISPAj), yellowish white color. Poor development of aerial hyphae.
胞子の着生貧弱。コロニー裏面は黄味臼。可溶性色素な
し。Poor spore settlement. The back side of the colony is yellowish. No soluble dyes.
グリセリン・アスパラギン寒天培地(ISPAj) 生育良好、黄味白色。気菌糸の発達貧弱。Glycerin-asparagine agar medium (ISPAj) Good growth, yellowish white. Poor development of aerial hyphae.
胞子の着生貧弱。コロニー裏面は黄味白色。Poor spore settlement. The underside of the colony is yellowish white.
可溶性色素なし。No soluble dyes.
チロシン培地(ISPA7)
生育良好、黄茶色。気菌糸の発達貧弱。胞子の着生貧弱
。コロニー裏面は黄茶色。可溶性色素なし。Tyrosine medium (ISPA7) Good growth, yellowish brown. Poor development of aerial hyphae. Poor spore settlement. The underside of the colony is yellowish brown. No soluble dyes.
シュクロース・硝酸塩寒天培地 生育貧弱、白色。気菌糸の発達貧弱。胞子形成中程度。Sucrose/nitrate agar medium Poor growth, white color. Poor development of aerial hyphae. Moderate sporulation.
コロニー裏面は白色。可溶性色素なし。The underside of the colony is white. No soluble dyes.
グルコース・アスパラギン寒天培地 生育良好、黄味白色。気菌糸の発達は貧弱。Glucose-asparagine agar medium Good growth, yellowish white. Aerial mycelium development is poor.
胞子形成良好。可溶性色素なし。コロニー裏面は黄味白
色。Good sporulation. No soluble dyes. The underside of the colony is yellowish white.
ベネソト寒天培地
生育良好、白色〜黄味臼。気菌糸の発達旺盛。胞子形成
貧弱。コロニー裏面は黄味白〜黄茶色。可溶性色素なし
。Good growth on Benesoto agar medium, white to yellowish color. Strong development of aerial mycelium. Poor sporulation. The underside of the colony is yellowish white to yellowish brown. No soluble dyes.
普通寒天培地 生育中程度、黄味白。気菌糸の発達貧弱。Ordinary agar medium Medium growth, yellowish white. Poor development of aerial hyphae.
胞子形成貧弱。コロニー裏面は黄味白色。可溶性色素な
し。Poor sporulation. The underside of the colony is yellowish white. No soluble dyes.
リンゴ酸カルシウム培地 生育良好、白色。気菌糸の発達貧弱。胞子の着生貧弱。Calcium malate medium Good growth, white color. Poor development of aerial hyphae. Poor spore settlement.
コロニー裏面は白色。可溶性色素なし。The underside of the colony is white. No soluble dyes.
3 生理学的性質
/)生育温度範囲:ベネット寒天培地上において20〜
37℃の温度範囲で生育し1.27〜3O℃の範囲で良
好に生育する。3. Physiological properties/) Growth temperature range: 20 to 30% on Bennett agar medium
It grows in the temperature range of 37°C and grows well in the range of 1.27 to 30°C.
2)ゼラチンの液化:陽性
3)スターチの加水分解:陽性
り 硝酸塩の還元:陽性
左)脱脂乳のペプトン化:陽性
〃 凝固 :陽性
6)耐塩性:2%食塩含有培地中で生育するが、グ%以
上では生育しない。2) Liquefaction of gelatin: Positive 3) Hydrolysis of starch: Positive Reduction of nitrate: Positive Left) Peptonization of skim milk: Positive Coagulation: Positive 6) Salt tolerance: Grows in a medium containing 2% salt, but It will not grow above 5%.
7) メラニン様色素の生成:メラニン用チロシン寒天
培地上で陰性。7) Production of melanin-like pigment: Negative on tyrosine agar medium for melanin.
g)炭素源の資化性(プリドハム・ゴトリープの基礎培
地〕
D−グルコースニ+、D−キシロース:+L〜アラビノ
ース:+、L−ラムノースニー/17
D−フIクトース:+、D−マンニトール:+ラフィノ
ース:±、シュクロースニー
1−イノシトール:±
ダ 細胞壁組成
ベソカー(Becker )等の方法〔アプライドマイ
クロバイオロジー(Appl、 Microbiol、
) 。g) Assimilation of carbon sources (basal medium of Pridham gotrib) D-glucoseni+, D-xylose: +L~arabinose: +, L-rhamnoseni/17 D-fuctose: +, D-mannitol: + Raffinose: ±, Shucrosny 1-inositol: ± da Cell wall composition Method of Becker et al. [Applied Microbiology (Appl, Microbiol,
).
/3,23&、/945)により分析した結果、本菌株
(A2g2)の細胞壁の主要成分はLL−A−2pm及
びグリシンを含有する細胞壁タイプ■型であることが判
明した。/3, 23&, /945) revealed that the main components of the cell wall of this strain (A2g2) were cell wall type 2 containing LL-A-2pm and glycine.
5 分類学的考察
本菌株(A21:2)はコロニー色調が白色〜黄味白色
を呈し、培養日数が経過しても灰色になることはない。5. Taxonomic Consideration The colony color of this strain (A21:2) is white to yellowish white, and does not turn gray even after culture days have passed.
メラニン様色素を産生しない。胞子形成様式は分節型様
式を示し、胞子着生部はゆるやかなラセン状構造を示す
。Does not produce melanin-like pigments. The sporulation mode is segmental, and the spore-bearing area shows a gentle spiral structure.
胞子表面は平滑。Spore surface is smooth.
これらの特徴について、Nonomura Cジャーナ
ルオプフアーメンテーションテクノロジー(J、 Fe
rment、 Technol、 )、 !r 、2.
7ざ−qa、/qqia〕によって提案されているSt
reptomyces属のrsp菌種の検索表に拠って
、種の検索を行った。Regarding these characteristics, Nonomura C Journal Opinion Technology (J, Fe
rment, Technol, ), ! r, 2.
7za-qa, /qqia] proposed by St.
A species search was performed using a search table for RSP species of the genus Reptomyces.
その結果、本菌株(k2g2)はStrepto−my
ces albusに類似した種であることが示唆され
た。As a result, this strain (k2g2) was found to have Strepto-mycobacteria.
It was suggested that it is a species similar to ces albus.
そこでE、 B、 Shirling & D、 Go
ttlieb、 Int。So E, B, Shirling & D, Go
ttlieb, Int.
J、、 5yst、 Bact、、 / 9. pH
O/ (/ 949 )に記載されているS、 aLb
usの形態学的性状、培養上の性質及び糖の資化性等と
本菌(A2g2)の各種性状を対比したところ、本菌株
はS。J,,5yst,Bact,,/9. pH
S, aLb described in O/ (/949)
When we compared the morphological properties, culture properties, sugar assimilation properties, etc. of S. us with various properties of this strain (A2g2), we found that this strain was S.
albusの記載に一致した。It matched the description of albus.
よって本菌株(A、2g 2 )はStreptomy
cesalbusと同定した。Therefore, this strain (A, 2g 2 ) is a streptomy
It was identified as cesalbus.
上記菌株は、工業技術院微生物工業技術研究所に微工研
菌寄第9g92号(FERMP−9g92)として寄託
されている。The above-mentioned strain has been deposited with the Institute of Microbial Technology, Agency of Industrial Science and Technology as FERMP-9g92.
本微生物を用いて上記化合物を生産するにあたって用い
られる培地は炭素源、窒素源、及び無機塩更に必要に応
じて有機微量栄養素を適宜含有する通常の液体培地が用
いられろ。炭素源としては、例えばグルコース、フルク
トース、マルトース、シュクロース、スターチ、テキス
トリン、でんぷん加水分解物、廃糖蜜、水飴などの炭水
化物、クエン酸、コハク酸、フマル酸、酢酸、プロピオ
ン酸等の有機酸、ヤシ油、グリセリン等の油脂類が用い
られる。窒素源としては、例えば硫酸アンモニウム、塩
化アンモニウム、リン酸アンモニウム、硝酸アンモニウ
ム、酢酸アンモニウム、プロピオン酸アンモニウム等の
アンモニウム塩、硝酸ナトリウム、硝酸カリウムなどの
硝酸塩、尿素、アンモニア水、アンモニアガス、アミノ
酸類、更にペプトン、大豆フレーク、大豆粉及び、それ
らの加水分解物等の蛋白質、米糠、ファーマメディア、
サングレイン等が用いられる。その他無機塩としては、
例えばマンガン塩、リン酸塩、塩化物、硫酸塩、炭酸塩
、鉄塩、コバルト塩、ニッケル塩、カルシウム塩、亜鉛
塩、銅塩等が適宜用いられ、また有機微量栄養素として
はアミノ酸、ビタミン及びこれらを含有するペプトン、
肉エキス、ファーマメディア、サングレイン、酵母エキ
ス、コーンステイープリカー等が適宜用いられる。The medium used to produce the above compound using the present microorganism is a conventional liquid medium containing a carbon source, a nitrogen source, an inorganic salt, and, if necessary, organic micronutrients. Examples of carbon sources include carbohydrates such as glucose, fructose, maltose, sucrose, starch, texturin, starch hydrolysates, blackstrap molasses, and starch syrup, and organic acids such as citric acid, succinic acid, fumaric acid, acetic acid, and propionic acid. , coconut oil, glycerin, and other oils and fats are used. Examples of nitrogen sources include ammonium salts such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium nitrate, ammonium acetate, and ammonium propionate, nitrates such as sodium nitrate and potassium nitrate, urea, aqueous ammonia, ammonia gas, amino acids, and peptone, Proteins such as soybean flakes, soybean flour and their hydrolysates, rice bran, Pharmamedia,
Sungrain etc. are used. Other inorganic salts include
For example, manganese salts, phosphates, chlorides, sulfates, carbonates, iron salts, cobalt salts, nickel salts, calcium salts, zinc salts, copper salts, etc. are used as appropriate, and organic micronutrients include amino acids, vitamins, Peptone containing these,
Meat extract, Pharmamedia, sungrain, yeast extract, cornstarch liquor, etc. are used as appropriate.
培養条件は、培地組成その他により異なるが、例えば、
通常pHは中性付近、温度/&−’10℃で振盪培養、
通気攪拌培養など好気的条件下に培養が行われる。Culture conditions vary depending on medium composition and other factors, but for example,
Usually the pH is around neutral, the temperature is / -' 10℃, shaking culture,
Culture is performed under aerobic conditions such as aerated agitation culture.
本発明の化合物は水溶性の塩基性物質であり、主として
培養濾液中に含まれるので、例えば培養濾液を適宜の吸
着剤に接触させて有効成分を吸着させ、適宜の溶媒によ
り有効成分を脱着させる手段が有効に利用される。即ち
、ダイヤイオンHP−20(三菱化成社製)、アンバー
ライトXAD−7(ローム・アンド・バー、11)など
の合成吸着剤、シリカゲル、アルミナ等によるカラムク
ロマトグラフィー等が有効である。The compound of the present invention is a water-soluble basic substance and is mainly contained in the culture filtrate, so for example, the culture filtrate is brought into contact with an appropriate adsorbent to adsorb the active ingredient, and the active ingredient is desorbed with an appropriate solvent. Means are used effectively. That is, column chromatography using synthetic adsorbents such as Diaion HP-20 (manufactured by Mitsubishi Kasei Corporation) and Amberlite XAD-7 (Rohm & Barr, 11), silica gel, alumina, etc. are effective.
溶出溶媒には水溶性有機溶媒の含水溶液、例えば含水メ
タノール、含水ジオキサン等が用いられる。As the elution solvent, a water-containing solution of a water-soluble organic solvent, such as water-containing methanol or water-containing dioxane, is used.
以上のような方法により、或はこれらを適宜組み合わせ
ることにより、前述の理化学的性質を有する化合物を高
純度に得る事ができる。By using the above methods or by appropriately combining these methods, it is possible to obtain highly pure compounds having the above-mentioned physicochemical properties.
なお、各精製工程における目的物の検出方法は、イトマ
キヒトデ胚の発生を胞胚前期で選択的に停止させる活性
〔池上晋他:「バイオテクノロジー、生化学から物質生
産へ」丸尾文治編、p2gA、学会出版センター、/q
gs:]を用いてRNA合成阻害作用を測定した。即ち
、イトマキヒトデ受精卵を一定量の海水に懸濁し、本化
合物を一定量含有する海水溶液を添加し、75時間以上
培養を続ける。イトマキヒトデ受精卵が発生し、ふ化し
て海水中に遊泳するに至った個体の数を計測し、本物質
のイトマキヒトデに対する発生阻害作用を調べろ。The method for detecting the target substance in each purification step is the activity that selectively stops the development of starfish embryos at the early blastula stage [Susumu Ikegami et al.: "From biotechnology and biochemistry to material production" edited by Bunji Maruo, p2gA, Academic Society Publication Center, /q
gs:] was used to measure the RNA synthesis inhibitory effect. That is, a fertilized egg of a starfish is suspended in a certain amount of seawater, a seawater solution containing a certain amount of the present compound is added, and culture is continued for 75 hours or more. Count the number of fertilized sea star eggs that have hatched and swim in seawater, and investigate the developmental inhibitory effect of this substance on starfish.
本発明の抗腫瘍剤は、そのまま、あるいは塩酸塩のよう
な塩化合物に変換したものを非経口投与として溶液剤で
処方することで生体中の腫瘍を抑制せしめるために利用
することができる。The antitumor agent of the present invention can be used as it is, or by converting it into a salt compound such as a hydrochloride and prescribing it as a solution for parenteral administration, to suppress tumors in living organisms.
本発明の上記化合物の投与量は、病気の重さ、患者の体
重及び当患者が認める他の因子によって異なるが、通常
治療を必要とする患者(動物及びヒト)に対して患者当
り0.02〜5orvの全日用量で投与することができ
る。The dosage of the above compounds of the invention will vary depending on the severity of the disease, the weight of the patient and other factors recognized by the patient, but will usually be 0.02 mg/patient for patients (animals and humans) in need of treatment. A total daily dose of ~5 orv can be administered.
(実施例)
以下に製造例及び実施例を挙げてさらに本発明を具体的
に説明するが、その要旨を超えない限り以下に限定され
るものではない。(Example) The present invention will be further specifically explained below with reference to Production Examples and Examples, but the present invention is not limited to the following unless it exceeds the gist thereof.
製造例/
水飴1%、大豆油0.3%、グルコース7%、大豆粉2
%、ファーマメディア(ラングストンバック社)7%、
サングレイン(サングレイン社)0.3%、炭酸カルシ
ウム0.3%を含有する培地g 0m1(pH7,0)
に本菌株(Aug:1株)を接種し、2001nl三角
フラスコ内で前培養したのち、上記の組成の培地/クリ
ットルに接種し、3Oリツトルジヤー中で、27℃、g
日間通気培養した。ジャーコ基分の培養物をセライト濾
過して菌体を除いて、培養濾液20リツトルを得た。こ
の培養濾液は、イトマキヒトデ胚発生を胞胚形成直後の
37二−細胞期で選択的に停止させる活性を示した。上
で得られた培養源′0.20リットルを、ダイヤイオン
HP−2θのSリットルカラムに通し、水洗した後、1
00%メタノールで活性画分を溶出させた。濃縮、乾固
した後、シラン化シリカゲル(メルク社製)のコ、6×
35cIrLカラムにつけ、水洗した後、5%メタノー
ルにて活性画分を溶出させた。濃縮、乾固した後、ロー
バーRP−g(メルク社製)の4グX 、20cmカラ
ムに付し、70%メタノールにて活性画分を溶出させる
。濃縮、乾固した後、中性アルミナのカラム(/、/×
20CTL)に付し、メタノール−水(/:/)で溶出
させた後、メタノール−水(、?ニア)で活性画分は得
られる。高速液体クロマトグラフィーによりうシアルパ
ックC18カラム(ウォーターズ社製)をSO%メタノ
ールで溶出させると、はぼ純粋な結晶を4.4 m9得
た。その理化学的性質は以下のようであった。Production example: Starch syrup 1%, soybean oil 0.3%, glucose 7%, soybean flour 2
%, Pharmamedia (Langston Buck) 7%,
Medium g 0ml containing 0.3% Sungrain (Sungrain Co., Ltd.) and 0.3% calcium carbonate (pH 7.0)
This strain (Aug: 1 strain) was inoculated and precultured in a 2001nl Erlenmeyer flask, then inoculated into a medium/critre with the above composition, and incubated at 27°C in a 3O bottle jar.
Aerated culture was carried out for 1 day. The culture containing the Jerco base was filtered through Celite to remove bacterial cells to obtain 20 liters of culture filtrate. This culture filtrate showed the activity of selectively arresting starfish embryonic development at the 37 two-cell stage immediately after blastula formation. 0.20 liter of the culture source obtained above was passed through an S liter column of Diaion HP-2θ, washed with water, and then
The active fraction was eluted with 00% methanol. After concentrating and drying, silanized silica gel (manufactured by Merck & Co., Ltd.)
After applying to a 35cIrL column and washing with water, the active fraction was eluted with 5% methanol. After concentrating and drying, it was applied to a Rover RP-g (manufactured by Merck & Co., Ltd.) 4gX, 20cm column, and the active fraction was eluted with 70% methanol. After concentration and drying, a neutral alumina column (/, /×
After eluting with methanol-water (/:/), an active fraction is obtained with methanol-water (?near). High performance liquid chromatography was performed on a Cialpac C18 column (manufactured by Waters) eluting with SO% methanol to obtain 4.4 m9 of nearly pure crystals. Its physical and chemical properties were as follows.
(a) 分子量:267
(b) 分子式: C1l H13N3O5(C)元
素分析値
(d)融 点:10/、!i〜IOA、0℃(e)
溶解性:水、メタノール、エタノール、ジオキサン及び
ピリジンに可溶で、
クロロホルム及び酢酸エチルに難
溶である。(a) Molecular weight: 267 (b) Molecular formula: C1l H13N3O5 (C) Elemental analysis value (d) Melting point: 10/,! i~IOA, 0℃(e)
Solubility: Soluble in water, methanol, ethanol, dioxane and pyridine, slightly soluble in chloroform and ethyl acetate.
(f) 第1図に示す紫外部吸収スペクトルを有する
。(f) It has the ultraviolet absorption spectrum shown in FIG.
(g) 第2図に示す核磁気共鳴スペクトルを有する
。(g) It has the nuclear magnetic resonance spectrum shown in FIG.
(h) 第3図に示す赤外線吸収スペクトルを有する
。(h) It has an infrared absorption spectrum shown in FIG.
実施例/(癌化ヒト繊維芽細胞に対する影響)イーグル
MEM粉末培地(田水製薬製の高圧蒸気滅菌可能細胞培
養用培地成分) q、+ gを蒸留水に溶解し、全量を
/リットルとした後、727℃で75分間高圧蒸気滅菌
した。高圧蒸気滅菌後、室温まで冷やした培地に無菌7
0%炭酸水素ナトリウム水溶液を適量加え、培地のpH
を7.qとした。これに無菌のし一グルタミンを0.
J 9 :1g加えた後、無菌の牛胎児血清(A、rm
our社製〕を100m1添加して細胞培養培地を調製
した。この培地に予め培養したヒト癌KMsT−4M胞
(ナンバマサヨシ他:International J
ournal of Cancer、 35゜275−
一ざ0,19gり)を細胞濃度グ、0×IO’m13で
加え、この細胞懸濁液を=9穴マイクロテストプレート
(ファルコン社製)K1ml無菌的に分注し、炭酸ガス
インキュベーター中で炭酸ガス濃度s%、温度37℃の
条件下2q時間培養した。この培養液に本化合物を一定
量含有する上記培地を0./ ml添加し、更に2日間
培養を継続し、トリバンプルーを用いる細胞染色法によ
り生細胞数を計測し、本物質のKMST−6細胞に対す
る生育阻害作用を調べた。その結果を第7表に示した。Example/(Effect on cancerous human fibroblasts) Eagle MEM powder medium (Cell culture medium component that can be autoclaved and steam sterilized, manufactured by Tadami Seiyaku) q, + g was dissolved in distilled water, and the total volume was adjusted to /liter. Thereafter, it was autoclaved at 727°C for 75 minutes. After high-pressure steam sterilization, the medium is cooled to room temperature.
Add an appropriate amount of 0% sodium bicarbonate aqueous solution to adjust the pH of the medium.
7. I made it q. Add 0.0% sterile glutamine to this.
J9: After adding 1g, sterile fetal bovine serum (A, rm
A cell culture medium was prepared by adding 100 ml of the following product (manufactured by our company). Human cancer KMsT-4M cells (Nanba Masayoshi et al.: International J.
Our own of Cancer, 35°275-
Add 0.19g of the cell suspension at a cell concentration of 0.13g and 0xIO'm13, and aseptically dispense this cell suspension into 1ml of a 9-well microtest plate (manufactured by Falcon) in a carbon dioxide incubator. Culture was carried out for 2 q hours under conditions of carbon dioxide gas concentration s% and temperature 37°C. Add 0.0% of the above medium containing a certain amount of the present compound to this culture solution. / ml was added, and the culture was continued for another 2 days. The number of living cells was counted by cell staining method using trivan blue, and the growth inhibitory effect of this substance on KMST-6 cells was investigated. The results are shown in Table 7.
なお、表中(−)は生育阻害のないことを示しく ++
+ )は全ての細胞が死滅することを示す。In addition, (-) in the table indicates that there is no growth inhibition.
+) indicates that all cells die.
第1表
濃 度 KMST−6細胞
(μg/rnl) の生育阻害度0、OII
千十
〇、コO+++
/、 0 + + +九〇
+++++は50〜7S%の阻
害度
+++はり5〜100%の阻害反
実施例コ(マウス乳癌細胞に対する影響)マウス乳癌細
胞F M 、? A細胞(小山方接9組織培養、A、2
3!;−2’1.3,19g0)に対する生育阻害効果
を記す。ES粉末培地(日永製薬社製の高圧蒸気滅菌可
能細胞培養用培地成分99.7gを蒸留水に溶解し、全
量を7リノトルとした後、727℃で7S分間高圧蒸気
滅菌した。Table 1 Concentration Growth inhibition degree of KMST-6 cells (μg/rnl) 0, OII
110, Ko +++ /, 0 + + +90
+++++ is an inhibition degree of 50-7S% +++ is an inhibition of 5-100% (influence on mouse mammary cancer cells) Mouse mammary cancer cells F M ? A cells (Koyama Katsuki 9 tissue culture, A, 2
3! ;-2'1.3,19g0). 99.7 g of ES powder medium (high-pressure steam sterilizable cell culture medium component manufactured by Hinaga Pharmaceutical Co., Ltd.) was dissolved in distilled water to make a total volume of 7 liters, followed by high-pressure steam sterilization at 727° C. for 7 S minutes.
高圧蒸気滅菌後、室温まで冷やした培地に無菌70%炭
酸水素ナトリウム水溶液を適量加え培地のpHを7.+
とじた。これに無菌のL−グルタミンを0.292 、
!9加え、無菌の牛胎児血清(Armour社製)を2
0’rnl添加して細胞培養培地を調製した。この培地
に、予め培養したFMJA細胞を7. OX / O5
/mlの細胞濃度となるように加え、この細胞懸濁液を
2ダ穴マイクロテストプレート(ファルコン社製)に/
me無菌的に分注し、炭酸ガスインキュベーター中で
炭酸ガス濃度5%、温度37℃の条件下3時間培養した
。この培養液に本化合物を一定量含有する上記培地を0
. / ml添加し、更に2日間培養を継続し、トリバ
ンブルーを用いる細胞染色法により生細胞数を計測し、
本物質のFM、?A細胞に対する生育阻害作用を調べた
。その結果を第2表に示した。After autoclaving, add an appropriate amount of sterile 70% sodium bicarbonate aqueous solution to the medium cooled to room temperature to adjust the pH of the medium to 7. +
Closed. Add 0.292 sterile L-glutamine to this,
! 9, and sterile fetal bovine serum (manufactured by Armor)
A cell culture medium was prepared by adding 0'rnl. 7. Add pre-cultured FMJA cells to this medium. OX/O5
/ml, and this cell suspension was placed in a 2-well microtest plate (manufactured by Falcon).
The mixture was dispensed aseptically and cultured in a carbon dioxide incubator for 3 hours at a carbon dioxide concentration of 5% and a temperature of 37°C. Add 0 of the above medium containing a certain amount of this compound to this culture solution.
.. / ml was added, the culture was continued for another 2 days, and the number of living cells was counted by a cell staining method using Trivan blue.
FM of this substance? The growth inhibitory effect on A cells was investigated. The results are shown in Table 2.
第2表
濃度 マウス乳癌細胞由来FM、7A細胞に対す
る増殖阻害率
7J &/!
tj 、22
.33.OA2
乙3.0 9/15
θ、099
第2表に示されるように、本化合物はマウス乳癌細胞F
M、?Aに対してLDsoは、27 n g /mlで
あった。Table 2 Concentration Mouse breast cancer cell-derived FM, growth inhibition rate for 7A cells 7J &/!
tj, 22
.. 33. OA2 Otsu 3.0 9/15
θ, 099 As shown in Table 2, this compound was used in mouse breast cancer cells F
M,? The LDso for A was 27 ng/ml.
(発明の効果)
本発明の上記化合物は、ヒト繊維芽細胞やマウス乳癌細
胞の増殖を抑制することから、抗腫瘍剤として有用であ
る。(Effects of the Invention) The above compound of the present invention suppresses the proliferation of human fibroblasts and mouse breast cancer cells, and is therefore useful as an antitumor agent.
第1図は、本発明化合物の紫外部吸収スペクトルを衣わ
す図面である。
第2図は、本発明化合物の核磁気共鳴スペクトルを表わ
す図面である。
第3図は、本発明化合物の赤外線吸収スペクトルを表わ
す図面である。FIG. 1 is a diagram showing the ultraviolet absorption spectrum of the compound of the present invention. FIG. 2 is a drawing showing the nuclear magnetic resonance spectrum of the compound of the present invention. FIG. 3 is a drawing showing the infrared absorption spectrum of the compound of the present invention.
Claims (1)
られ、下記理化学的性質を有する化合物を有効成分とす
る抗腫瘍剤。 (a)分子量:267 (b)分子式:C_1_1H_1_3N_3O_5(c
)元素分析値 ▲数式、化学式、表等があります▼ (C_1_1H_1_3N_3O_5・CH_3OHと
して)(d)融点:101.5〜106.0℃ (e)溶解性:水、メタノール、エタノール、ジオキサ
ン及びピリジンに可溶 で、クロロホルム及び酢酸エチ ルに難溶である。 (f)第1図に示す紫外部吸収スペクトルを有する。 (g)第2図に示す核磁気共鳴スペクトルを有する。 (h)第3図に示す赤外線吸収スペクトルを有する。(1) An antitumor agent containing as an active ingredient a compound obtained from Streptomyces albus A282 bacteria and having the following physicochemical properties. (a) Molecular weight: 267 (b) Molecular formula: C_1_1H_1_3N_3O_5(c
) Elemental analysis values ▲ Numerical formulas, chemical formulas, tables, etc. ▼ (as C_1_1H_1_3N_3O_5・CH_3OH) (d) Melting point: 101.5-106.0℃ (e) Solubility: Possible in water, methanol, ethanol, dioxane and pyridine It is slightly soluble in chloroform and ethyl acetate. (f) It has the ultraviolet absorption spectrum shown in FIG. (g) It has the nuclear magnetic resonance spectrum shown in FIG. (h) It has an infrared absorption spectrum shown in FIG.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63054319A JPH01228483A (en) | 1988-03-08 | 1988-03-08 | Antitumor agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63054319A JPH01228483A (en) | 1988-03-08 | 1988-03-08 | Antitumor agent |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH01228483A true JPH01228483A (en) | 1989-09-12 |
Family
ID=12967264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63054319A Pending JPH01228483A (en) | 1988-03-08 | 1988-03-08 | Antitumor agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01228483A (en) |
-
1988
- 1988-03-08 JP JP63054319A patent/JPH01228483A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0182315B1 (en) | Novel antibiotic nk84-0218 pharmaceutical compositions containing it and process for the production of the same | |
JPS643877B2 (en) | ||
JPS58180487A (en) | Antibiotic dc-81 and its preparation | |
JPH0631279B2 (en) | Antibacterial / antitumor compound and method for producing the same | |
JPS6215560B2 (en) | ||
US5013550A (en) | Antibiotics called "chloropolysporins B and C", a process for their preparation, and their therapeutic and veterinary use | |
US4539203A (en) | CL-1577D And CL-1577E antibiotic/antitumor compounds, their production and use | |
KR920001448B1 (en) | Bbm-2478 antibiotic complex | |
KOMORI et al. | LAVENDOMYCIN, A NEW ANTIBIOTIC I. TAXONOMY, ISOLATION AND CHARACTERIZATION | |
CA1207694A (en) | Anthracycline compounds, process for production thereof, and uses thereof | |
DE3003624A1 (en) | ANTIBIOTICA C-19393 S LOW 2 AND H LOW 2 | |
JPH01228483A (en) | Antitumor agent | |
JPH0147479B2 (en) | ||
FI101402B (en) | A method for preparing a new antibiotic, balhimycin | |
HU184846B (en) | Process for producing homo-citric acid-oligoryboside derivatives | |
JPS63218681A (en) | Oligomycin e | |
JPS60156392A (en) | Fr-900336 substance and its preparation | |
JPH01149791A (en) | Compound tan-999, production and use thereof | |
EP0727420A1 (en) | Novel antibiotic and process for producing the same | |
JP2989662B2 (en) | Benaltin, a novel enzyme inhibitor, and its production | |
EP0429209B1 (en) | New antibiotic chemical compound "DC 114-C" | |
JPS59148795A (en) | Anthracycline compound, its preparation and use | |
JP4495817B2 (en) | Anticancer antibiotics thiazinotrienomycin F and G and antibiotic benzoxazomycin | |
JPH08239379A (en) | Kr 2827 derivative as new substance, its production and use | |
JP2795489B2 (en) | New substance DC115A compound |